BDR Pharma introduces prostate cancer drug with enhanced strength

BDR Pharmaceuticals on Monday said it has launched prostate cancer treatment drug Enzalutamide in 160 mg strength.

The company has introduced the medication, under the brand name BDENZA 160mg, at Rs 6,300 for a strip of seven tablets.

The medicine was previously available in 40 mg and 80 mg strength for which patients had to consume two tablets a day.

The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment, BDR Pharmaceuticals said in a statement.

“Our focused launch of such expanded brand strength will definitely add value to Indian oncology patients as well as provide opportunity for medical physicians to comply with patient outcome and standard treatment protocol.

“This represents a firm commitment to providing access to affordable medicines for Indian cancer patients with high quality standards,” BDR Pharmaceuticals Director Business Development Raheel Shah noted.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor